Top Markets
Coin of the day
Miravant Medical Technologies Inc. Miravant Medical Technologies Inc.

Miravant Medical Technologies Inc.

MRVT
Rang in Aktien #42699
Miravant Medical Technologies Inc. operates as a specialized firm dedicated to... Miravant Medical Technologies Inc. operates as a specialized firm dedicated to pharmaceutical research and development. A cornerstone of its work involves PhotoPoint, an innovative photodynamic therapy designed to eradicate cancerous cells when exposed to light. Furthermore, the company manufactures the essential light-generating and light-delivery devices required for this treatment. Miravant's product pipeline includes several therapeutic agents: PHOTREX, which is aimed at treating wet age-related macular degeneration (AMD); MV9411, a photoreactive compound developed for managing plaque psoriasis; MV0633, which targets conditions like atherosclerosis, vulnerable atherosclerotic plaque, and restenosis; MV2101, designed to address vascular access graft disease in hemodialysis patients; and MV6401, a treatment under development for solid tumors. The organization, originally established as PDT, Inc., officially adopted its current name, Miravant Medical Technologies Inc., in September of 1997. Founded in 1989, it maintains its corporate headquarters in Santa Barbara, California.
Aktienkurs
$0.00001
Zuletzt synchronisiert: 2025-06-16
Marktkapitalisierung
$352.62
Veränderung (1 Tag)
-99.67%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Miravant Medical Technologies Inc. (MRVT)

Kategorie

P/B-Verhältnis für Miravant Medical Technologies Inc. (MRVT)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Miravant Medical Technologies Inc. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für Miravant Medical Technologies Inc. von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber